Active Ingredient History
Relacorilant is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome. It is also under development for the treatment of solid tumors and alcoholism. The drug is a nonsteroidal compound and acts as an antagonist of the glucocorticoid receptor. As of December 2017, it is in phase II clinical trials for Cushing's syndrome and phase I/II clinical studies for solid tumors, while the clinical phase for alcoholism is unknown. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adrenocortical Carcinoma (Phase 1)
Cushing Syndrome (Phase 3)
Fallopian Tube Neoplasms (Phase 3)
Hamartoma (Phase 2)
Healthy Volunteers (Phase 1)
Liver Diseases (Phase 1)
Neoplasms (Phase 1)
Ovarian Neoplasms (Phase 3)
Pancreatic Neoplasms (Phase 3)
Peritoneal Neoplasms (Phase 3)
Prostatic Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue